People's Journal of Scientific Research
Published December 1, 2012 | Version v1
Journal article Open

Fenofibrate: A novel approach in treating uncomplicated neonatal hyperbilirubinemia?

Authors/Creators

  • 1. Department of Pharmacology, Rama Medical College, Hospital & Research Centre, Mandhana, Kanpur - 209217
  • 2. Department of Pharmacology, R.D. Gardi Medical College & Hospital, Surasa, Ujjain-456006
  • 3. Department of Pediatrics, R.D. Gardi Medical College & Hospital, Surasa, Ujjain-456006

Description

Fenofibrate is one of the commonest drug to treat hyperlipidemia in adults (Marshall et al, 2011). However, apart from its hypolipidemic action, it also has the ability to induce bilirubin conjugation. The present study was aimed to find its effect on uncomplicated neonatal hyperbilirubinemia. The study was conducted on 40 normal term newborns who were admitted for uncomplicated jaundice at R.D. Gardi Medical College & Hospital, Ujjain from March 2010 to October 2010. The data included: age, sex, weight, serum bilirubin level, and duration of hospitalization. All newborns enrolled in this study, received phototherapy. The cases were divided into two groups viz. Fenofibrate group (B) consisting of 14 boys (70%) and 6 girls (30%) and a control group (A) with 11boys (55%) and 9 girls (45%). There were no statistical overt differences between the two groups regarding sex distribution, age, weight and total serum bilirubin level at the time of admission. Mean values for total serum bilirubin in Fenofibrate group at 12, 24, 36, and 48 hours after starting of phototherapy were significantly lower than those for control group (p<0.00l). The mean time needed for phototherapy was also shorter in Group B than Group A. Fenofibrate appears to be an effective drug for neonatal hyperbilirubinemia. This decreases the duration of phototherapy and thus reduces the length of hospital stay.

Files

2 Bijay Kumar.pdf

Files (31.3 kB)

Name Size Download all
md5:418e13119809819fbc530945fd39f7fc
31.3 kB Preview Download

Additional details

References

  • 1. American Academy of Pediatrics, subcommittee on Hyperbilirubinemia: Clinical practice guidelines: Management of Hyperbilirumia in the newborn infant 35 or more weeks of gestation. Pediatrics, 2004;114:297- 316.
  • 2. Bennet PN, Brown MJ: Clinical Pharmacology (Section 5). 10th Edn. Churchill Livingstone: An Imprint of Elsevier, New Delhi. 2008;pp.474-475.
  • 3. Bourget P, Broise I, Quinquis Desmaris V, Gablin JC: Pharmacokinetics of Clofibrate in jaundiced newborn infants at term. Archives of Pediatrics., 1995;2(8):722 728.
  • 4. Dennery PA: Pharmacological interventions for the treatment of neonatal jaundice. Seminars in Neonatalogy, 2002;7(2):111-119.
  • 5. Elam M, Lovato LC, Ginsberg H: Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective.Current Opinion in Lipidology, 2011; 22(1): 55-61.
  • 6. Gabilan JC, Benattar C, Lindenbaum A: Clofibrate treatment of neonatal jaundice. Pediatrics, 1990;86(4):647-648.
  • 7. Gottstein R, Cooke R: Systematic review of intravenous immunoglobulin in hemolytic disease of the newborn. Archives of Disease in Child hood: fetal & neonatal edition, 2003;88:F6-F10.
  • 8. Kappas A, Drummond GS, Valaes T: A single dose of snmesoporphyrin prevents development of severe hyperbilirubinemia in glucose-6-phosphate dehydrogenase-defficient newborns. Pediatrics, 2001;108:25-30.
  • 9. Kutz K, Kandler H, Gugler R, Fevery J: Effect of Clofibrate on the metabolism of bilirubin, Bromosulphophthalein and indocyanine green and on the biliary lipid composition in Gilberts syndrome. Clinical Science, 1984;66(4):389-397.
  • 10. Maisels MJ, Kring E: The contribution of hemolysis to early jaundice in normal newborns. Pediatrics 2006;118(1):276-279.
  • 11. Mohammadzadeh A, Farhat A SH, Iranpour R: Effect of Clofibrate in jaundiced term newborns. Indian Journal Pediatrics, 2005;72(2):123-126.
  • 12. Newman TB, Liljestrand P, Jeremy RJ, Ferriero Dm, Wu YW, Hudes ES, Escdar GJ: Outcomes among newborns with total serum bilirubin levels of 25 mg per deciliter or more. The New England Journal of Medicine, 2006;354(18):1889-1900.
  • 13. Piazza AJ, Stoll BJ: The fetus and the neonatal infantDigestive system disorders (Kernicterus). In: Nelson Text Book of Pediatrics (Vol. I). RM Kliegman, RE Behrman, HB Jenson, BF Stanton (Eds.); 18th Edn.; Saunders: An imprint of Elsevier, Philadelphia; 2008.pp.761-765
  • 14. Harris MC, Roth P: Neonatology. In: Pediatrics Secret. A Richard, RA Polin & MF Ditmer (Eds.); 1st Edn.; Hanley & Belfus, Philadelphia, 1989;p.261.
  • 15. Scott R, O'Briten R, Fulcher G, Pardy C, d'Emden M, Tse D, Taskinen MR: Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic synndrome: the FIELD study. Diabetes Care, 2009; 32(3):493-498.
  • 16. Sterm L, Khanna NN, Levy G: Effect of Phenobarbitone on hyperbilirubinemia and glucuronide formation in newborn. Archives of pediatrics & Adolescent Medicine, 1970;120(1):2631.
  • 17. Watchko JF: Vigintiphobia revisited. Pediatrics, 2005;115(6):1747-1753